thromboxane-a2 and glyceryl-2-arachidonate

thromboxane-a2 has been researched along with glyceryl-2-arachidonate* in 3 studies

Reviews

1 review(s) available for thromboxane-a2 and glyceryl-2-arachidonate

ArticleYear
Activation of platelets by the endocannabinoids 2-arachidonoylglycerol and virodhamine is mediated by their conversion to arachidonic acid and thromboxane A2, not by activation of cannabinoid receptors.
    Platelets, 2014, Volume: 25, Issue:6

    Topics: Arachidonic Acids; Blood Platelets; Cannabinoid Receptor Agonists; Cannabinoids; Endocannabinoids; Glycerides; Humans; Platelet Activation; Receptors, Cannabinoid; Thromboxane A2

2014

Other Studies

2 other study(ies) available for thromboxane-a2 and glyceryl-2-arachidonate

ArticleYear
Detrimental effects of 2-arachidonoylglycerol on whole blood platelet aggregation and on cerebral blood flow after a focal ischemic insult in rats.
    American journal of physiology. Heart and circulatory physiology, 2018, 05-01, Volume: 314, Issue:5

    2-Arachidonoylglycerol (2-AG) is a major modulator of blood flow and platelet aggregation and a potential neuroprotectant. The present study investigated, for the first time, the effects of 2-AG on cerebral blood flow (CBF) in the first critical hours during middle cerebral artery occlusion (MCAO) and on platelet aggregation in rats. Adult male Sprague-Dawley rats ( n = 30) underwent permanent MCAO under isoflurane anesthesia and were randomly assigned to receive either 2-AG (6 mg/kg iv), monoacylglycerol lipase inhibitor JZL-184 (10 mg/kg iv), or vehicle ( n = 6 rats/group) treatment. CBF and cardiovascular responses were measured, by a blinded investigator, for up to 4 h. In separate experiments, platelet aggregation by 2-AG (19-300 µM) was assessed by whole blood aggregometry ( n = 40). 2-AG and JZL-184 significantly increased the severity of the CBF deficit versus vehicle (20.2 ± 8.8% and 22.7 ± 6.4% vs. 56.4 ± 12.1% of pre-MCAO baseline, respectively, P < 0.05) but had no effect on blood pressure or heart rate. While JZL-184 significantly increased the number of thrombi after MCAO, this did not reach significance by 2-AG. 2-AG induced platelet aggregation in rat whole blood in a similar manner to arachidonic acid and was significantly reduced by the cyclooxygenase inhibitors indomethacin and flurbiprofen and the thromboxane receptor antagonist ICI 192,605 ( P < 0.05). This is the first study showing that 2-AG increases the severity of the CBF deficit during MCAO, and further interrogation confirmed 2-AG-induced platelet aggregation in rats. These findings are important because 2-AG had previously been shown to exert neuroprotective actions and therefore force us to reevaluate the circumstances under which 2-AG is beneficial. NEW & NOTEWORTHY 2-Arachidonoylglycerol (2-AG) has neuroprotective properties; however, the present study revealed that 2-AG increases the severity of the cerebral blood flow deficit during middle cerebral artery occlusion in rats. Further interrogation showed that 2-AG induces platelet aggregation in rats. These findings force us to reevaluate the circumstances under which 2-AG is beneficial.

    Topics: Animals; Arachidonic Acids; Blood Platelets; Cerebrovascular Circulation; Disease Models, Animal; Endocannabinoids; Glycerides; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Rats, Sprague-Dawley; Severity of Illness Index; Thromboxane A2; Time Factors

2018
2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products.
    Cardiovascular research, 2004, Jul-01, Volume: 63, Issue:1

    Endocannabinoids have been shown to play a role in the regulation of vascular tone. The effects of 2-arachidonoyl glycerol (2-AG) on induced-tone were examined in rat aortic rings in vitro.. Aortic rings from Wistar Kyoto (WKY) rats were suspended in organ chambers for recording isometric tension development in response to 2-AG. The production of TXA2 in response to 2-AG was also assessed by enzyme immunoassay.. In endothelium-intact rings pre-contracted to PGF(2alpha), 2-AG (10 nM-30 microM) induced a biphasic effect: a weak relaxation from 10 nM to 0.1 microM, which turned into a concentration-dependent contraction from 3 to 30 microM. Endothelium-denudation did not change 2-AG-mediated vascular effects. 2-AG-induced contraction was unaffected by both the cannabinoid CB1 receptor antagonist SR141716A (3 microM) and the CB2 receptor antagonist SR144528 (1 microM). In contrast, the anandamine transport inhibitor (AM404, 100 microM) and the amino hydrolase inhibitor (PMSF, 30 microM) attenuated (P<0.05) the contractile response evoked by 2-AG in endothelium-intact and rubbed aortic rings. In addition, the cyclooxygenase inhibitor (indomethacin, 10 microM) and the thromboxane A2 (TXA2) receptor (TP receptor) antagonist GR32191 (0.3 microM) totally abolished the contraction elicited by 2-AG in endothelium-intact and rubbed aortic rings. Challenge of isolated aortic rings with 2-AG (10 microM) evoked a significant increase in TXA2 level (measured as TXB2 level) in endothelium-intact and rubbed aortic rings.. These data suggested that the contraction elicited by 2-AG resulted from the vascular smooth muscle cell uptake and conversion of 2-AG to constrictor prostanoid TXA2, which in turn caused vasoconstriction through the stimulation of TP receptor.

    Topics: Animals; Aorta; Arachidonic Acids; Cannabinoid Receptor Modulators; Dinoprost; Dinoprostone; Endocannabinoids; Glycerides; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Inbred WKY; Thromboxane A2; Vasoconstrictor Agents

2004